Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Grace Therapeutics, Inc
Bullboard Posts
User Avatar Image
(61)
•••
Comment by Canadian_101on Jun 14, 2020 8:16am
268 Views
Post# 31147926

RE:We shall see

RE:We shall seeI cannot see the FDA totally shutting everything down for ASCTI and providing no way forward at all, they may have them redo the trial for the sites that showed weird results or they may say take those results out of the total, with close to 90 percent of the sites showing excellent results it would be hard for the FDA to say that the product did not work at all. What we also have to keep in mind is that there are lots of markets that do not need US FDA approvals plus there are  huge secondary markets for the drug. 

"The Phase 2 data also showed a significant reduction of HbA1c at a 4 gram dose, suggesting that due to its unique omega-3/phospholipid composition, CaPre may actually improve long-term glucose metabolism."

Holding my shares as well, both the new ones bought at 35 cents and the ones bought at a buck, hopefully this proves to be a smart decision or may lead to a divorce...LOL., time will tell.




Ryeman40 wrote: Screw it got 20,000 more shares friday. Maybe i swing maybe i hold. I still have all my original shares from 3 yrs ago. Should know better next week hopefully. 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities